文献速递免疫规划传染病防控与疫情报告

埃博拉病毒GP蛋白258-601氨基酸鼻内接种联合佐剂可保护小鼠免受致死性攻击

Intranasal vaccination with ebola virus GP amino acids 258-601 protects mice against lethal challenge.
PubMed 文献 · Vaccine · 2018-09-06

本研究以原核表达纯化的埃博拉病毒GP蛋白胞外域(N20)联合黏膜佐剂CTA1-DD(H45)经鼻内免疫小鼠,评估其免疫原性与对小鼠适应株EBOV攻击的保护效果。结果显示H45佐剂化N20可激发体液、Th1细胞及黏膜免疫,并使小鼠完全抵御致死性攻击且体重丢失等副作用少;单用N20或H45的小鼠则死亡。作者认为该黏膜疫苗是预防埃博拉的潜在候选。

要点

  • 鼻内接种H45佐剂化N20可诱导GP特异性IgG、Th1型细胞免疫及阴道冲洗液抗EBOV IgA。
  • 该疫苗完全保护小鼠抵御致死性小鼠适应株EBOV攻击,体重丢失提示副作用少。
  • 仅接受N20或H45的小鼠在致死性攻击后死亡。

核心结论

  • 鼻内接种H45佐剂化N20可激发体液、Th1细胞和黏膜免疫,并完全保护小鼠抵御致死性小鼠适应株EBOV攻击,副作用少(基于体重丢失)。
  • 作者认为该黏膜疫苗是有效、安全、便捷的埃博拉预防潜在候选疫苗。

研究设计与样本

  • 研究以原核表达并经色谱纯化的EBOV GP蛋白胞外域(N20)为抗原,以CTA1-DD(H45)为黏膜佐剂,经鼻内途径免疫小鼠,并评估对小鼠适应株EBOV攻击的保护效果。
  • 原文未报告小鼠样本量、分组数及具体免疫程序。

主要发现

  • H45佐剂化N20鼻内接种可刺激GP特异性IgG抗体滴度升高,提示体液免疫应答。
  • 基于IgG亚类及IFN-γ/IL-4分泌细胞检测,疫苗诱导Th1型细胞免疫。
  • 阴道冲洗液中检出抗EBOV IgA,提示黏膜免疫应答。
  • H45佐剂化N20完全保护小鼠抵御致死性小鼠适应株EBOV攻击,体重丢失提示副作用少。
  • 仅接受N20或H45的小鼠在致死性小鼠适应株EBOV攻击后死亡。

关键数值与推荐

  • 原文未报告具体的IgG滴度数值、IgG亚类比例、IFN-γ/IL-4分泌细胞数及保护率数值。
  • 原文未报告疫苗剂量、免疫次数与间隔。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ebola virus (EBOV) disease (EVD) leads to lethal hemorrhagic fever with a case fatality rate as high as 90%, thus posing a serious global public health concern. However, while several vaccines based on the EBOV glycoprotein have been confirmed to be effective in animal experiments, no licensed vaccines or effective treatments have been approved since the first outbreak was reported in 1976. In this study, we prepared the extracellular domain of the EBOV GP protein (designated as N20) by prokaryotic expression and purification via chromatography. Using CTA1-DD (designated as H45) as a mucosal adjuvant, we evaluated the immunogenicity of N20 by intranasal administration and the associated protective efficacy against mouse-adapted EBOV challenge in mice. We found that intranasal vaccination with H45-adjuvanted N20 could stimulate humoral immunity, as supported by GP-specific IgG titers; Th1 cellular immunity, based on IgG subclasses and IFN-γ/IL-4 secreting cells; and mucosal immunity, based on the presence of anti-EBOV IgA in vaginal lavages. We also confirmed that the vaccine could completely protect mice against a lethal mouse-adapted EBOV (MA-EBOV) challenge with few side effects (based on weight loss). In comparison, mice that received N20 or H45 alone succumbed to lethal MA-EBOV challenge. Therefore, mucosal vaccination with H45-adjuvanted N20 represents a potential vaccine candidate for the prevention of EBOV in an effective, safe, and convenient manner.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Su QD, He SH, Yi Y, et al. Intranasal vaccination with ebola virus GP amino acids 258-601 protects mice against lethal challenge. Vaccine. 2018. PMID: 30195490. doi:10.1016/j.vaccine.2018.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。